What is the most recent earnings date for HSCS stock?
HEARTSCIENCES INC (HSCS) last reported earnings on 3/16/2026.
NASDAQ:HSCS • US42254E3027
Past quarterly earnings results for HEARTSCIENCES INC (HSCS), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2026 | -0.63 | -0.87 | 27.34% | 75.49% | - | - | ||
| Q2 2026 | -0.85 | -2.01 | 57.81% | 62.56% | 2K | 51K | -96.08% | - |
| Q1 2026 | -1.58 | -1.94 | 18.47% | 40.15% | 2K | - | - | |
| Q4 2025 | -1.88 | -2.30 | 18.08% | 90.01% | 4.35K | - | - | |
| Q3 2025 | -2.57 | -2.42 | -6.31% | 14.33% | - | -100.00% | ||
| Q2 2025 | -2.27 | -2.48 | 8.42% | 85.81% | 357K | -100.00% | -100.00% | |
| Q1 2025 | -2.64 | -2.51 | -5.00% | 79.69% | 153K | -100.00% | - | |
| Q4 2024 | -18.81 | -3.57 | -426.89% | 10.43% | 51K | -100.00% | - | |
| Q3 2024 | -3.00 | -6.12 | 50.98% | 81.25% | 14.7K | - | 673.68% | |
| Q2 2024 | -16.00 | -12.24 | -30.72% | 27.27% | 3.9K | - | - | |
| Q1 2024 | -13.00 | -14.28 | 8.96% | -4,542.86% | - | -100.00% | ||
| Q4 2023 | -21.00 | -16.32 | -28.68% | - | - | -100.00% | ||
| Q3 2023 | -16.00 | -16.83 | 4.93% | - | 1.9K | - | -29.63% | |
| Q2 2023 | -22.00 | -34.17 | 35.62% | - | - | - | ||
| Q1 2023 | -0.28 | - | - | 3.2K | - | -57.33% | ||
| Q4 2022 | - | - | 4.2K | - | -71.81% | |||
| Q3 2022 | - | - | 2.7K | - | -74.65% | |||
| Q2 2022 | - | - | - | - | ||||
| Q1 2022 | - | - | 7.5K | - | - | |||
| Q4 2021 | - | - | 14.9K | - | - | |||
| Q3 2021 | - | - | 10.65K | - | - |
Notes
HEARTSCIENCES INC (HSCS) last reported earnings on 3/16/2026.
HEARTSCIENCES INC (HSCS) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, HEARTSCIENCES INC (HSCS) has beaten EPS estimates in 4 out of 4 releases.